Donald C. Goff mainly focuses on Schizophrenia, Psychosis, Internal medicine, Psychiatry and Neuroscience. His Schizophrenia research incorporates elements of NMDA receptor, Recall and Cognition. His research in Psychosis intersects with topics in Clozapine, Audiology, Memoria, Clinical psychology and Cognitive disorder.
His Internal medicine research is multidisciplinary, incorporating perspectives in Diabetes mellitus, Endocrinology, Placebo and Gastroenterology. His Placebo research is multidisciplinary, incorporating elements of Anesthesia, Randomized controlled trial and Abstinence. He interconnects Clinical trial, Disease and Intensive care medicine in the investigation of issues within Psychiatry.
His main research concerns Schizophrenia, Psychiatry, Psychosis, Internal medicine and Neuroscience. His Schizophrenia research includes themes of Placebo, Cognition and Clinical psychology. His work carried out in the field of Placebo brings together such families of science as Anesthesia and Positive and Negative Syndrome Scale.
His Psychiatry study combines topics in areas such as Clinical trial and Epidemiology. His Psychosis research is multidisciplinary, relying on both NMDA receptor, Developmental psychology, Hippocampal formation, Hippocampus and Cognitive disorder. His research integrates issues of Risperidone, Endocrinology, Olanzapine and Atypical antipsychotic in his study of Internal medicine.
His primary areas of investigation include Schizophrenia, Psychiatry, Internal medicine, Placebo and Neuroscience. His Schizophrenia study integrates concerns from other disciplines, such as Biomarker, Psychosis, Clinical trial and Clinical psychology. His study in Psychosis is interdisciplinary in nature, drawing from both Hippocampal formation, Molecular biology and Psychological intervention.
His Psychiatry study which covers Adverse effect that intersects with Fluphenazine, Social stress and Acute intoxication. His Internal medicine research incorporates elements of Risperidone, Relapse prevention and Endocrinology. His Placebo research includes themes of Psychopathology, Scale for the Assessment of Negative Symptoms, Brief Psychiatric Rating Scale, Pharmacology and Positive and Negative Syndrome Scale.
Donald C. Goff focuses on Schizophrenia, Psychiatry, Placebo, Internal medicine and Randomized controlled trial. The concepts of his Schizophrenia study are interwoven with issues in Psychosis, Prefrontal cortex, Clinical psychology and Neuroscience, Brain mapping. Donald C. Goff is studying Schizoaffective disorder, which is a component of Psychiatry.
The Placebo study which covers Scale for the Assessment of Negative Symptoms that intersects with Vitamin B12 and Surgery. He interconnects Gastroenterology, Allele and Positive and Negative Syndrome Scale in the investigation of issues within Internal medicine. His Randomized controlled trial research is multidisciplinary, incorporating elements of Clozapine, Discontinuation, Relapse prevention, Risperidone and Antipsychotic.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Joseph Patrick McEvoy;Jonathan M. Meyer;Donald C. Goff;Henry A. Nasrallah.
Schizophrenia Research (2005)
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Donald C. Goff;Joseph T. Coyle.
American Journal of Psychiatry (2001)
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
David C. Henderson;Enrico Cagliero;Colin Gray;Rima A. Nasrallah.
American Journal of Psychiatry (2000)
Regionally Localized Thinning of the Cerebral Cortex in Schizophrenia
Gina R. Kuperberg;Matthew R. Broome;Philip K. McGuire;Anthony S. David.
Archives of General Psychiatry (2003)
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
Donald C. Goff;David C. Henderson;Edward Amico.
American Journal of Psychiatry (1992)
Impaired recruitment of the hippocampus during conscious recollection in schizophrenia.
Stephan Heckers;Scott L. Rauch;Donald Goff;Cary R. Savage.
Nature Neuroscience (1998)
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.
Henry A. Nasrallah;Jonathan M. Meyer;Donald C. Goff;Joseph Patrick McEvoy.
Schizophrenia Research (2006)
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
Donald C. Goff;Lisa M. Sullivan;Joseph Patrick McEvoy;Jonathan M. Meyer.
Schizophrenia Research (2005)
Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance.
Dara S Manoach;Randy L Gollub;Etienne S Benson;Meghan M Searl.
Biological Psychiatry (2000)
A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia
Robert W Buchanan;Miriam Davis;Donald Goff;Michael F Green.
Schizophrenia Bulletin (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: